Endoscopic Treatment of Benign Biliary Strictures and Cystic Duct Leakages With a Novel Biodegradable Biliary Stent

Sponsor
Tampere University Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT02353286
Collaborator
(none)
14
1
2
44
0.3

Study Details

Study Description

Brief Summary

Patients with either post-cholecystectomy bile leak or benign biliary stricture are recruited for endoscopic insertion of a biodegradable biliary stent. A follow-up of 12 months with repeated serum samples and magnetic resonance imaging is scheduled. The primary end points are feasibility of endoscopic insertion with the novel implantation device and stricture or leak resolution as well as clinical treatment success.

Condition or Disease Intervention/Treatment Phase
  • Device: Endoscopic insertion of biodegradable biliary stent
N/A

Detailed Description

Benign biliary strictures (BBS) and post-cholecystectomy bile leaks have traditionally been treated endoscopically with plastic stents. In BBS, promising results of covered self-expanding metal stent use have been recently published. However, in both BBS and post-cholecystectomy bile leak the need of stent therapy is temporary and endoscopic stent exchange or removal is unavoidable. These two groups of patients may be the ones that would most obviously benefit from biodegradable (BD) biliary stents. Studies of BD stents on animal models have shown excellent long term patency and safety both in biliary and pancreatic duct as well better outcome compared to plastic stents after post-cholecystectomy bile leak in an animal study. Until recently, non-operative insertion of BD polydioxanone stent in human biliary tract has been possible only via percutaneous route.

With the novel implantation device, the BD stents (braided, self-expanding polydioxanone stent, 8 x 40-60mm, Ella, Czech republic) may be used endoscopically during endoscopic retrograde cholangio-pancreatography (ERCP).

The hypothesis is that larger diameter and radial expansion strength provide at least similar treatment success as the current method of endoscopic insertion of plastic or covered self-expanding metal stents in bile leak and BBS, respectively. However, later stent exchange or removal is not necessary with BD stents.

Study Design

Study Type:
Interventional
Actual Enrollment :
14 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Endoscopic Treatment of Benign Biliary Strictures and Cystic Duct Leakages With a Novel Biodegradable Polydioxanone Biliary Stent
Study Start Date :
May 1, 2014
Actual Primary Completion Date :
Dec 31, 2017
Actual Study Completion Date :
Dec 31, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Post-cholecystecomy bile leak

Endoscopic insertion of biodegradable biliary stent

Device: Endoscopic insertion of biodegradable biliary stent
Endoscopic insertion of biodegradable biliary stent
Other Names:
  • Braided, self-expanding polydioxanone stent, Ella, Czech Rep
  • Experimental: Benign biliary stricture

    Endoscopic insertion of biodegradable biliary stent

    Device: Endoscopic insertion of biodegradable biliary stent
    Endoscopic insertion of biodegradable biliary stent
    Other Names:
  • Braided, self-expanding polydioxanone stent, Ella, Czech Rep
  • Outcome Measures

    Primary Outcome Measures

    1. Clinical treatment success of stricture or leakage, treatment failure rate measured by change in treatment protocol or unplanned interventions, radiologic stricture diameter in MRI, radiologic stent degradation in MRI [The follow-up of 12 months after stent implantation]

      Stent patency, unplanned admissions and interventions, signs of cholangitis during treatment assessed by repeated liver function tests, magnetic resonance imaging and interview. Change in stent diameter and gradual radiologic dissappearance due to degradation assessed by repeated MRI and liver function tests, stricture resolution assessed by repeated MRI and radiologic measurement of stricture width as well as liver function tests, leakage resolution assessed by disappearance of biliary fluid collection in MRI and liver function tests

    Secondary Outcome Measures

    1. ERCP complications, late adverse events during stent therapy [30 days from stent implantation, late adverse events up to 12 months]

      endoscopic retrograde cholangio-pancreatography (ERCP) and stent implantation related complications graded mild-moderate-severe according to Cotton et al 1991, unplanned admissions and incidence of late adverse events such as acute cholangitis until up to 12 months of follow-up assessed by repeated MRI, phone interview, blood samples and review of patient records at each follow-up contact.

    2. Technical success of stent insertion [intraoperative]

      To assess the usefulness and safety of a novel endoscopic implantation device measured by success rate of stent implantation and evaluation possible intra-procedural technical challenges during ERCP

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • informed-consent patients with diagnosed or suspected post-cholecystectomy biliary leak or benign biliary stricture.
    Exclusion Criteria:
    • Patients with contra-indications for magnetic resonance imaging (MRI) or surgically altered gastro-duodenal anatomy (e.g. roux-y-loop) are excluded from the study.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tampere University Hospital, Dept. of Gastroenterology and Alimentary Tract Surgery Tampere Finland 33521

    Sponsors and Collaborators

    • Tampere University Hospital

    Investigators

    • Study Director: Johanna Laukkarinen, Md, PhD, Dept. of Gastroenterology and Alimentary Tract Surgery
    • Study Director: Juhani Sand, Md, PhD, Dept. of Gastroenterology and Alimentary Tract Surgery

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Antti Siiki, MD, Tampere University Hospital
    ClinicalTrials.gov Identifier:
    NCT02353286
    Other Study ID Numbers:
    • Biodegradable Biliary stent
    First Posted:
    Feb 2, 2015
    Last Update Posted:
    May 14, 2018
    Last Verified:
    May 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by Antti Siiki, MD, Tampere University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 14, 2018